Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Unit differences in pathogen occurrence arising from the MYSTIC program European database (1997-2000).

C Mendes1, P J Turner,

  • 1Laboratório Fleury, São Paulo, Brazil

Diagnostic Microbiology and Infectious Disease
|January 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emergency treatment of peri-operative anaphylaxis: Resuscitation Council UK algorithm for anaesthetists.

Anaesthesia·2024
Same author

Pre-existing influenza-specific nasal IgA or nasal viral infection does not affect live attenuated influenza vaccine immunogenicity in children.

Clinical and experimental immunology·2020
Same author

Atrial matrix remodeling in atrial fibrillation patients with aortic stenosis.

BMC cardiovascular disorders·2020
Same author

Comment on 'Four-year data from use of the nut and soya allergy testing protocol before treatment with isotretinoin and alitretinoin'.

Clinical and experimental dermatology·2020
Same author

The risk of Kawasaki disease after pneumococcal conjugate & meningococcal B vaccine in England: A self-controlled case-series analysis.

Vaccine·2020
Same author

Differences in nasal immunoglobulin A responses to influenza vaccine strains after live attenuated influenza vaccine (LAIV) immunization in children.

Clinical and experimental immunology·2019

The Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program found meropenem highly effective against common pathogens like E. coli and MSSA. Carbapenems and piperacillin/tazobactam maintained high susceptibility, crucial for selecting empiric antimicrobial regimens.

Area of Science:

  • Infectious Diseases
  • Clinical Microbiology
  • Pharmacology

Background:

  • Antimicrobial resistance is a growing global health concern.
  • Surveillance programs are essential for monitoring pathogen susceptibility patterns.
  • Understanding regional and unit-specific resistance is vital for effective treatment.

Purpose of the Study:

  • To evaluate the in vitro activity of meropenem and other agents against key pathogens.
  • To compare antimicrobial susceptibility across different patient populations and hospital units.
  • To inform optimal empiric antimicrobial therapy selection.

Main Methods:

  • Analysis of data from the European Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program (1997-2000).
  • In vitro susceptibility testing of common bacterial isolates including methicillin-susceptible Staphylococcus aureus (MSSA), Pseudomonas aeruginosa, and Escherichia coli.

Related Experiment Videos

  • Comparison of meropenem and various comparator agents.

    • Main Results:

    • Meropenem demonstrated high susceptibility rates (>97%) against E. coli and MSSA.
    • P. aeruginosa showed low susceptibility to ciprofloxacin and gentamicin but remained highly susceptible to meropenem and piperacillin/tazobactam.
    • Extended spectrum beta-lactamase (ESBL) phenotype was observed in approximately 20% of E. coli isolates.

    Conclusions:

    • Meropenem and piperacillin/tazobactam are highly effective against frequently isolated pathogens, including P. aeruginosa.
    • Carbapenems and piperacillin/tazobactam consistently show >90% susceptibility rates.
    • Continued surveillance in high-risk units is critical for guiding empiric antimicrobial treatment strategies.